The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Blood Neurofilament Light Chain: The Neurologist’s Troponin?
Open accessAbstract
Blood neurofilament light chain (NfL) is a marker of neuro-axonal injury showing promising associations with outcomes of interest in several neurological conditions. Although initially discovered and investigated in the cerebrospinal fluid (CSF), the recent development of ultrasensitive digital immunoassay technologies has enabled reliable detection in serum/plasma, obviating the need for invasive lumbar punctures for longitudinal assessment. The most evidence for utility relates to multiple sclerosis (MS) where it serves as an objective measure of both the inflammatory and degenerative pathologies that characterise this disease. In this review, we summarise the physiology and pathophysiology of neurofilaments before focusing on the technological advancements that have enabled reliable quantification of NfL in blood. As the test case for clinical translation, we then highlight important recent developments linking blood NfL levels to outcomes in MS and the next steps to be overcome before this test is adopted on a routine clinical basis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“NfL is a structural protein that can be detected in the blood at elevated levels in a variety of neurological diseases (2–5).”
From A Method to Combine Neurofilament Light Measurements From Blood Serum and Plasma in Clinical and Population-Based Studies (2022) · cites this paper as [2]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis
Lennon, V. A., Wingerchuk, D. M., Kryzer, T. J., Pittock, S. J., Lucchinetti, C. F., Fujihara, K., Nakashima, I., & Weinshenker, B. G. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17551-x · Cited by 3,239
Neurofilaments as biomarkers in neurological disorders
Khalil, M., Teunissen, C. E., Otto, M., Piehl, F., Sormani, M. P., Gattringer, T., Barro, C., Kappos, L., Comabella, M., Fazekas, F., et al. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0058-z · Cited by 1,988
Ruiter, A. M., Meilof, J. F., Somanje-Bolweg, R. R. J., van Gorsel, E., & Kalkers, N. F. (2017) · Case Reports in Neurology · doi:10.1159/000455942 · Cited by 1,762
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
Bloomgren, G., Richman, S., Hotermans, C., Subramanyam, M., Goelz, S. E., Natarajan, A., Lee, S., Plavina, T., Scanlon, J. V., Sandrock, A. W., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1107829 · Cited by 1,260
Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis
Disanto, G., Barro, C., Benkert, P., Naegelin, Y., Schädelin, S., Giardiello, A., Zecca, C., Blennow, K., Zetterberg, H., Leppert, D., et al. (2017) · Annals of Neurology · doi:10.1002/ana.24954 · Cited by 1,164
A Structural Scaffolding of Intermediate Filaments in Health and Disease
Fuchs, E. V., & Cleveland, D. W. (1998) · Science · doi:10.1126/science.279.5350.514 · Cited by 1,013
Acute axonal injury in multiple sclerosis: Correlation with demyelination and inflammation
Bitsch, A. (2000) · Brain · doi:10.1093/brain/123.6.1174 · Cited by 898
Ofatumumab versus Teriflunomide in Multiple Sclerosis
Hauser, S. L., Bar‐Or, A., Cohen, J. A., Comı, G., Correale, J. D., Coyle, P. K., Cross, A. H., Seze, J. D., Leppert, D., Montalbán, X., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917246 · Cited by 765
Bridel, C., van Wieringen, W. N., Zetterberg, H., Tijms, B. M., Teunissen, C. E., and the NFL Group, Alvarez-Cermeño, J. C., Andreasson, U., Axelsson, M., Bäckström, D. C., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1534 · Cited by 764
Neurofilaments and Neurofilament Proteins in Health and DiseasePreprint
Yuan, A., Rao, M. V., Veeranna, & Nixon, R. A. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a018309 · Cited by 741
Kuhle, J., Barro, C., Andreasson, U., Derfuss, T., Lindberg, R., Sandelius, Å., Liman, V., Norgren, N., Blennow, K., & Zetterberg, H. (2016) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2015-1195 · Cited by 740
Carare, R. O., Bernardes‐Silva, M., Newman, T. A., Page, A. M., Nicoll, J. A. R., Perry, V. H., & Weller, R. O. (2008) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2007.00926.x · Cited by 665
Khalil, M., Pirpamer, L., Hofer, E., Voortman, M. M., Barro, C., Leppert, D., Benkert, P., Ropele, S., Enzinger, C., Fazekas, F., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14612-6 · Cited by 572
Blood neurofilament light chain as a biomarker of MS disease activity and treatment response
Kühle, J., Kropshofer, H., Häring, D. A., Kundu, U., Meinert, R., Barro, C., Dahlke, F., Tomic, D., Leppert, D., & Kappos, L. (2019) · Neurology · doi:10.1212/wnl.0000000000007032 · Cited by 568
Barro, C., Benkert, P., Disanto, G., Tsagkas, C., Amann, M., Naegelin, Y., Leppert, D., Gobbi, C., Granziera, C., Yaldizli, Ö., et al. (2018) · Brain · doi:10.1093/brain/awy154 · Cited by 517
on behalf of the MAGNIMS study group (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.157 · Cited by 473
Wilson, D. H., Rissin, D. M., Kan, C. W., Fournier, D. R., Piech, T., Campbell, T. G., Meyer, R. E., Fishburn, M. W., Cabrera, C., Patel, P. P., et al. (2015) · SLAS TECHNOLOGY · doi:10.1177/2211068215589580 · Cited by 470
Figlewicz, D. A., Krizus, A., Martinoli, M., Meininger, V., Dib, M., Rouleau, G. A., & Julien, J. (1994) · Human Molecular Genetics · doi:10.1093/hmg/3.10.1757 · Cited by 467
Monitoring disease activity in multiple sclerosis using serum neurofilament light protein
Novakova, L., Zetterberg, H., Sundström, P., Axelsson, M., Khademi, M., Gunnarsson, M., Malmeström, C., Svenningsson, A., Olsson, T., Piehl, F., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004683 · Cited by 426
Mersiyanova, I., Perepelov, A. V., Polyakov, A. V., Sitnikov, V. F., Леонидовна, Д. Е., Oparin, R. B., Petrin, A. N., & Evgrafov, O. V. (2000) · The American Journal of Human Genetics · doi:10.1086/302962 · Cited by 421
Bomont, P., Cavalier, L., Blondeau, F., Hamida, C. B., Belal, S., Tazir, M., Demir, E., Topaloğlu, H., Korinthenberg, R., Tüysüz, B., et al. (2000) · Nature Genetics · doi:10.1038/81701 · Cited by 408
MOG cell-based assay detects non-MS patients with inflammatory neurologic disease
Waters, P. J., Woodhall, M. R., O’Connor, K. C., Reindl, M., Lang, B., Sato, D. K., Juryńczyk, M., Tackley, G., Rocha, J., Takahashi, T., et al. (2015) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000089 · Cited by 402
Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab
Gunnarsson, M., Malmeström, C., Axelsson, M., Sundström, P., Dahle, C., Vrethem, M., Olsson, T. P., Piehl, F., Norgren, N., Rosengren, L., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22247 · Cited by 346
Neurofilaments: neurobiological foundations for biomarker applications
Gafson, A., Barthélemy, N. R., Bomont, P., Carare, R. O., Durham, H. D., Julien, J., Kühle, J., Leppert, D., Nixon, R. A., Weller, R. O., et al. (2020) · Brain · doi:10.1093/brain/awaa098 · Cited by 339
Confounding effect of blood volume and body mass index on blood neurofilament light chain levels
Manouchehrinia, A., Piehl, F., Hillert, J., Kuhle, J., Alfredsson, L., Olsson, T., & Kockum, I. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.50972 · Cited by 249
Dephosphorylation of neurofilament proteins enhances their susceptibility to degradation by calpain
Pant, H. C. (1988) · Biochemical Journal · doi:10.1042/bj2560665 · Cited by 238
The clinical course of multiple sclerosis
Confavreux, C., & Vukusic, S. (2014) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52001-2.00014-5 · Cited by 232
Yuan, A., Rao, M. V., Sasaki, T., Chen, Y., Kumar, A. R., Veeranna, Liem, R. K. H., Eyer, J., Peterson, A. C., Julien, J., et al. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.2580-06.2006 · Cited by 215
Siller, N., Kühle, J., Muthuraman, M., Barro, C., Uphaus, T., Groppa, S., Kappos, L., Zipp, F., & Bittner, S. (2018) · Multiple Sclerosis Journal · doi:10.1177/1352458518765666 · Cited by 213
Phosphorylation protects neurofilaments against proteolysis
Goldstein, M. E., Sternberger, N. H., & Sternberger, L. A. (1987) · Journal of Neuroimmunology · doi:10.1016/0165-5728(87)90049-x · Cited by 206
Serum neurofilament is associated with progression of brain atrophy and disability in early MS
Kühle, J., Nourbakhsh, B., Grant, D., Morant, S. V., Barro, C., Yaldizli, Ö., Pelletier, D., Giovannoni, G., Waubant, E. L., & Gnanapavan, S. (2017) · Neurology · doi:10.1212/wnl.0000000000003653 · Cited by 203
Piehl, F., Kockum, I. S., Khademi, M., Blennow, K., Lycke, J., Zetterberg, H., & Olsson, T. P. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517715132 · Cited by 184
Forgrave, L. M., Ma, M., Best, J. R., & DeMarco, M. L. (2019) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.08.009 · Cited by 177
Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity
Högel, H., Rissanen, E., Barro, C., Matilainen, M., Nylund, M., Kühle, J., & Airas, L. M. (2018) · Multiple Sclerosis Journal · doi:10.1177/1352458518819380 · Cited by 176
Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS
Bergman, J., Dring, A. M., Zetterberg, H., Blennow, K., Norgren, N., Gilthorpe, J. D., Bergenheim, T. A., & Svenningsson, A. (2016) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000271 · Cited by 166
Neurofilament light chain predicts disease activity in relapsing-remitting MS
Varhaug, K. N., Barro, C., Bjørnevik, K., Myhr, K., Torkildsen, Ø., Wergeland, S., Bindoff, L. A., Kühle, J., & Vedeler, C. A. (2017) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000422 · Cited by 164
Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis
Thebault, S., Abdoli, M., Fereshtehnejad, S., Tessier, D. R., Tabard‐Cossa, V., & Freedman, M. S. (2020) · Scientific Reports · doi:10.1038/s41598-020-67504-6 · Cited by 163
Self-citationSerum neurofilament light as a biomarker in progressive multiple sclerosis
Kapoor, R., Smith, K. E., Allegretta, M., Arnold, D. L., Carroll, W. M., Comabella, M., Furlan, R., Harp, C. T., Kühle, J., Leppert, D., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000010346 · Cited by 159
Quiroz, Y. T., Zetterberg, H., Reiman, E. M., Chen, Y., Su, Y., Fox-Fuller, J. T., Garcia, G., Villegas, A., Sepulveda-Falla, D., Villada, M., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30137-x · Cited by 159
A specific ELISA for measuring neurofilament heavy chain phosphoforms
Petzold, A., Keir, G., Green, A. J. E., Giovannoni, G., & Thompson, E. J. (2003) · Journal of Immunological Methods · doi:10.1016/s0022-1759(03)00189-3 · Cited by 158
A comparative study of CSF neurofilament light and heavy chain protein in MS
Kuhle, J., Plattner, K., Bestwick, J. P., Lindberg, R. L., Ramagopalan, S. V., Norgren, N., Nissim, A., Malaspina, A., Leppert, D., Giovannoni, G., et al. (2013) · Multiple Sclerosis Journal · doi:10.1177/1352458513482374 · Cited by 155
Neurofilament light chain serum levels correlate with 10‐year MRI outcomes in multiple sclerosis
Chitnis, T., Gonzalez, C. T., Healy, B. C., Saxena, S., Rosso, M., Barro, C., Michalak, Z., Paul, A., Kivisäkk, P., Diaz‐Cruz, C., et al. (2018) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.638 · Cited by 150
Novakova, L., Axelsson, M., Khademi, M., Zetterberg, H., Blennow, K., Malmeström, C., Piehl, F., Olsson, T. P., & Lycke, J. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13881 · Cited by 147
Yuan, A., Sasaki, T., Kumar, A., Peterhoff, C. M., Rao, M. V., Liem, R. K. H., Julien, J., & Nixon, R. A. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.1081-12.2012 · Cited by 146
Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit
Silber, E., Semra, Y. K., Gregson, N. A., & Sharief, M. K. (2002) · Neurology · doi:10.1212/wnl.58.9.1372 · Cited by 143
Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis
Kühle, J., Leppert, D., Petzold, A., Regeniter, A., Schindler, C., Mehling, M., Anthony, D. C., Kappos, L., & Lindberg, R. L. P. (2011) · Neurology · doi:10.1212/wnl.0b013e31821432ff · Cited by 140
Blood neurofilament light levels segregate treatment effects in multiple sclerosis
Delcoigne, B., Manouchehrinia, A., Barro, C., Benkert, P., Michalak, Z., Kappos, L., Leppert, D., Tsai, J. A., Plavina, T., Kieseier, B. C., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000009097 · Cited by 139
Bittner, S., Steffen, F., Uphaus, T., Muthuraman, M., Fleischer, V., Salmen, A., Luessi, F., Berthele, A., Klotz, L., Meuth, S. G., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102807 · Cited by 130
Eikelenboom, M. J., Petzold, A., Lazeron, R. H. C., Silber, E., Sharief, M. K., Thompson, E. J., Barkhof, F., Giovannoni, G., Polman, C. H., & Uitdehaag, B. M. J. (2003) · Neurology · doi:10.1212/01.wnl.0000041496.58127.e3 · Cited by 127
An Immunoblot Study of Neurofilament Degradation In Situ and During Calcium‐Activated Proteolysis
Schlaepfer, W. W., Lee, C., LEE, V. M.-Y., & Zimmerman, U.-J. P. (1985) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1985.tb05442.x · Cited by 125
Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS
Akgün, K., Kretschmann, N., Haase, R., Proschmann, U., Kitzler, H. H., Reichmann, H., & Ziemssen, T. (2019) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000555 · Cited by 124
Serum NfL (Neurofilament Light Chain) Levels and Incident Stroke in Adults With Diabetes Mellitus
Korley, F. K., Goldstick, J. E., Mastali, M., Eyk, J. E. V., Barsan, W. G., Meurer, W. J., Sussman, J. B., Falk, H. J., & Levine, D. A. (2019) · Stroke · doi:10.1161/strokeaha.119.024941 · Cited by 117
MRI in the Diagnosis and Monitoring of Multiple Sclerosis: An Update
Wattjes, M. P., Steenwijk, M. D., & Stangel, M. (2015) · Clinical Neuroradiology · doi:10.1007/s00062-015-0430-y · Cited by 116
Sejbaek, T., Nielsen, H. H., Penner, N., Plavina, T., Mendoza, J. P., Martin, N. A., Elkjaer, M. L., Ravnborg, M. H., & Illes, Z. (2019) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-321321 · Cited by 108
Bsteh, G., Hegen, H., Teuchner, B., Amprosi, M., Berek, K., Ladstätter, F., Wurth, S., Auer, M., Pauli, F. D., Deisenhammer, F., et al. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517740216 · Cited by 105
Association of neuronal injury blood marker neurofilament light chain with mild-to-moderate COVID-19
Ameres, M., Brandstetter, S., Toncheva, A. A., Kabesch, M., Leppert, D., Kühle, J., & Wellmann, S. M. (2020) · Journal of Neurology · doi:10.1007/s00415-020-10050-y · Cited by 101
Jakimovski, D., Zivadinov, R., Ramanthan, M., Hagemeier, J., Weinstock‐Guttman, B., Tomic, D., Kropshofer, H., Fuchs, T. A., Barro, C., Leppert, D., et al. (2019) · Multiple Sclerosis Journal · doi:10.1177/1352458519881428 · Cited by 99
Cellular and Molecular Biology of Neuronal Intermediate Filaments
Fliegner, K. H., & Liem, R. K. H. (1991) · International review of cytology · doi:10.1016/s0074-7696(08)62018-5 · Cited by 96
Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis
Manouchehrinia, A., Stridh, P., Khademi, M., Leppert, D., Barro, C., Michalak, Z., Benkert, P., Lycke, J., Alfredsson, L. S., Kappos, L., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000009571 · Cited by 92
Millecamps, S., Gowing, G., Corti, O., Mallet, J. J., & Julien, J. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.5299-06.2007 · Cited by 87
Uher, T., McComb, M., Galkin, S., Srpova, B., Oechtering, J., Barro, C., Tyblova, M., Bergsland, N., Krasensky, J., Dwyer, M., et al. (2021) · Multiple Sclerosis Journal · doi:10.1177/1352458520912379 · Cited by 86
Jakimovski, D., Kühle, J., Ramanathan, M. K., Barro, C., Tomic, D., Hagemeier, J., Kropshofer, H., Bergsland, N., Leppert, D., Dwyer, M. G., et al. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.50872 · Cited by 82
Nielsen, H. H., Soares, C. B., Høgedal, S. S., Madsen, J. S., Hansen, R. B., Christensen, A. A., Madsen, C., Clausen, B. H., Frich, L. H., Degn, M., et al. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00448 · Cited by 79
Serum neurofilament light chain is a useful biomarker in pediatric multiple sclerosis
Reinert, M., Benkert, P., Wuerfel, J. T., Michalak, Z., Ruberte, E., Barro, C., Huppke, P., Stark, W., Kropshofer, H., Tomic, D., et al. (2020) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000749 · Cited by 72
Hashimoto, R., Nakamura, Y., Komai, S., Kashiwagi, Y., Tamura, K., Goto, T., Aimoto, S., Kaibuchi, K., Shiosaka, S., & Takeda, M. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0750373.x · Cited by 69
Kalm, M., Boström, M., Sandelius, Å., Eriksson, Y., Ek, C. J., Blennow, K., Björk‐Eriksson, T., & Zetterberg, H. (2017) · Brain Research · doi:10.1016/j.brainres.2017.05.011 · Cited by 67
High serum neurofilament light chain normalizes after hematopoietic stem cell transplantation for MS
Thebault, S., Tessier, D. R., Lee, H., Bowman, M., Bar‐Or, A., Arnold, D. L., Atkins, H. L., Tabard‐Cossa, V., & Freedman, M. S. (2019) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000598 · Cited by 62
Self-citationAxonal and oligodendrocyte-localized IgM and IgG deposits in MS lesions
Sádaba, M. C., Tzartos, J. S., Paı́no, C. L., García-Villanueva, M., Alvarez-Cermeño, J. C., Villar, L. M., & Esiri, M. M. (2012) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2012.03.020 · Cited by 59
Disease activity free status in MS
LUBLIN, F. D. (2011) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2011.08.001 · Cited by 51
Igra, M. S., Paling, D., Wattjes, M. P., Connolly, D. J. A., & Hoggard, N. (2017) · British Journal of Radiology · doi:10.1259/bjr.20160721 · Cited by 46
Ching, G. Y., & Liem, R. K. H. (1998) · Journal of Cell Science · doi:10.1242/jcs.111.3.321 · Cited by 43
Plasma neurofilaments correlate with disability in progressive multiple sclerosis patients
Ferraro, D., Guicciardi, C., Biasi, S. D., Pinti, M., Bedin, R., Camera, V., Vitetta, F., Nasi, M., Meletti, S., & Sola, P. (2019) · Acta Neurologica Scandinavica · doi:10.1111/ane.13152 · Cited by 42
Freedman, M. S., Thompson, E. J., Deisenhammer, F., Giovannoni, G., Grimsley, G., Keir, G., Öhman, S., Racke, M. K., Sharief, M., Sindic, C. J. M., et al. (2005) · Archives of Neurology · doi:10.1001/archneur.62.6.865 · Cited by 41
Self-citationDegradation of the Intermediate Filament Family by Gigaxonin
Bomont, P. (2015) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2015.07.009 · Cited by 38
Amor, S., van der Star, B. J., Boscá, I., Raffel, J., Gnanapavan, S., Watchorn, J., Kühle, J., Giovannoni, G., Baker, D., Malaspina, A., et al. (2014) · Multiple Sclerosis Journal · doi:10.1177/1352458514521887 · Cited by 35
Intraindividual Neurofilament Dynamics in Serum Mark the Conversion to Sporadic Parkinson's Disease
Wilke, C., dos Santos, M. C. T., Schulte, C., Deuschle, C., Scheller, D., Verbelen, M., Brockmann, K., von Thaler, A., Sünkel, U., Röeben, B., et al. (2020) · Movement Disorders · doi:10.1002/mds.28026 · Cited by 32
Mattioli, F., Bellomi, F., Stampatori, C., Mariotto, S., Ferrari, S., Monaco, S., Mancinelli, C. R., & Capra, R. (2020) · Journal of Neurology · doi:10.1007/s00415-020-09832-1 · Cited by 30
O’Connell, G. C., Alder, M. L., Smothers, C. G., Still, C. H., Webel, A. R., & Moore, S. M. (2020) · Brain Research · doi:10.1016/j.brainres.2020.146861 · Cited by 28
Expression of Neurofilament Subunits at Neocortical Glutamatergic and GABAergic Synapses
Bragina, L., & Conti, F. (2018) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2018.00074 · Cited by 26
The neurofilament light chain is not stable in vitro
Koel‐Simmelink, M. J. A., Teunissen, C. E., Behradkia, P., Blankenstein, M. A., & Petzold, A. (2011) · Annals of Neurology · doi:10.1002/ana.22438 · Cited by 25
Comparison of plasma and cerebrospinal fluid neurofilament light in a multiple sclerosis trial
de Flon, P., Laurell, K., Sundström, P., Blennow, K., Söderström, L., Zetterberg, H., Gunnarsson, M., & Svenningsson, A. (2019) · Acta Neurologica Scandinavica · doi:10.1111/ane.13078 · Cited by 24
Kühle, J., Kropshofer, H., Barro, C., Meinert, R., Häring, D. A., Leppert, D., Tomic, D., Dahlke, F., & Kappos, L. (2018) · Neurology · doi:10.1212/wnl.90.15_supplement.s8.006 · Cited by 20
Neurofilament light as an immune target for pathogenic antibodies
Puentes, F., van der Star, B. J., Boomkamp, S. D., Kipp, M., Boon, L., Boscá, I., Raffel, J., Gnanapavan, S., van der Valk, P., Stephenson, J., et al. (2017) · Immunology · doi:10.1111/imm.12797 · Cited by 17
Cross, A. H., Bennett, J. L., von Büdingen, H.-C., Carruthers, R. L., Edwards, K. R., Fallis, R. J., Fiore, D., Gelfand, J. M., Giacomini, P. S., Greenberg, B. M., et al. (2019) · Neurology · doi:10.1212/wnl.92.15_supplement.s56.008 · Cited by 16
Filippi, P., Vestenicka, V., Šiarnik, P., Siváková, M., Čopíková‐Cudráková, D., Belan, V., Hanes, J., Novák, M., Kollár, B., & Turčáni, P. (2020) · PubMed · Cited by 14
Late Breaking News Submissions
Castellazzi, M., Lamberti, G., Resi, M., Baldi, E., Caniatti, L., Perri, P., & Pugliatti, M. (2018) · Multiple Sclerosis Journal · doi:10.1177/1352458518799980 · Cited by 8
Research works printed but not linked: 2
- Kapoor, 2018, Natalizumab reduced serum levels of neurofilament light chain in secondary progressive multiple sclerosis patients from the phase 3 ASCEND study, Mult. Scler. J., 24, 988
- Kuhle, 2018, Neurofilament light levels in the blood of patients with secondary progressive MS are higher than in primary progressive MS and may predict brain atrophy in both MS subtypes, Mult. Scler. J., 24, 111
Cited by
Sorted by citations
Digital Twins for Multiple Sclerosis
Voigt, I., Inojosa, H., Dillenseger, A., Haase, R., Akgün, K., & Ziemssen, T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.669811 · Cited by 293
Freedman, M. S., Gnanapavan, S., Booth, R. A., Calabresi, P. A., Khalil, M., Kühle, J., Lycke, J., & Olsson, T. P. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.104970 · Cited by 216
Self-citationPrediction of good neurological outcome in comatose survivors of cardiac arrest: a systematic review
Sandroni, C., D’Arrigo, S., Cacciola, S., Hoedemaekers, C., Westhall, E., Kamps, M. J. A., Taccone, F. S., Poole, D., Meijer, F. J. A., Antonelli, M. M., et al. (2022) · Intensive Care Medicine · doi:10.1007/s00134-022-06618-z · Cited by 186
Bavato, F., Barro, C., Schnider, L. K., Simrén, J., Zetterberg, H., Seifritz, E., & Quednow, B. B. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02524-6 · Cited by 94
Duffy, D. C. (2023) · Lab on a Chip · doi:10.1039/d2lc00783e · Cited by 84
Metadata
- Authors
- Thebault, S., Booth, R. A., & Freedman, M. S.
- Affiliations
- University of Ottawa (CA)
- Corresponding author
- Thebault, Simon
- Freedman, Mark S.
- Venue
- Biomedicines
- Publisher
- MDPI AG
- Published
- 2020-11-21
- Volume
- 8
- Issue
- 11
- Pages
- 523
- ISSN
- 2227-9059 (ISSN-L)
- PMC
- PMC7700209
- OpenAlex
- W3110272217
- Cited by
- 101
- References
- 86
- Citations by year
- 2026: 12 · 2025: 22 · 2024: 16 · 2023: 19 · 2022: 20 · 2021: 12
- FWCI
- 1.95
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Biomedicines (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Health Sciences › Medicine › Clinical Neurology › Peripheral Neuropathies and Disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Hereditary Neurological Disorders
- Keywords
- neurofilaments, multiple sclerosis, serum biomarkers, digital immunoassay, disease-modifying therapy response, neurodegeneration, neuroinflammation, clinical translation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
